The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Results from Phase I study of alnuctamab administered intravenously & subcutaneously in R/R myeloma
Sandy Wong, MD, University of California San Francisco, San Francisco, CA, gives an update on a Phase I trial evaluating intravenous (IV) or subcutaneous alnuctamab in patients with relapsed/refractory (R/R) multiple myeloma (NCT03486067). Whilst IV alnuctamab was associated with high-grade cytokine release syndrome (CRS), the trial found that administering alnuctamab subcutaneously led to better efficacy and an improved safety profile. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Catalent Biologics: Consultancy; Bristol Myers Squibb: Research Funding; Caelum: Research Funding; Genentech: Research Funding; Patient Discovery: Research Funding; Fortis: Research Funding; GSK: Research Funding; Janssen: Research Funding; Sanofi: Membership on an entity’s Board of Directors or advisory committees; Dren Bioscience: Consultancy.
